Predicting immunogenicity of candidates promotes knowledge-based decisions for lead selection
Our Epibase® platform of in silico immunoprofiling services and in vitro cellular assays predict and compare the immunogenicity risk potential of your biotherapeutic candidates and over 500 known protein sequences. Epibase® in silico and in vitro platforms provide a comprehensive immunogenicity assessment package.
Designed for a wide range of targets:
- Antibodies and antibody fragments
- Biotherapeutic proteins
- Bispecifics
- Biosimilars/Biobetters
- Enzyme replacement therapies
- Plant and bacterial proteins
- Viral vectors
- Synthetic peptide
Supporting lead selection, ranking, optimization and design to identify lower risk candidates before proceeding to in vitro screening
Epibase® in silico (IS) is a T-cell epitope screening platform that analyzes and predicts the potential immunogenicity of proteins.
- The Epibase® tool predicts peptide/HLA binding
- Uses 3D structural characteristics of HLA receptors
- Statistical modelling based on experimentally determined binding affinities of peptides
- Epibase® utilizes population frequencies and covers 99% of the global population (85 HLA allotypes)
- Applies self-peptide filtering (e.g. human antibody germline)
- Enhanced filter recognizing ‘self’ on the level of T Cell Receptor (TCR) facing residues
Save time and money in development
- Our scientific experts perform the work, analyze results and provide consultation on data interpretation
- Rapidly assess biotherapeutic proteins with a high throughput process
- Streamline candidate selection using in silico screening to select lower risk candidates before proceeding to in vitro screening
- Focus R&D resources on a smaller number of protein targets with the greatest chance of success early in development
Our Epibase® in vitro platform directly measures the immune response induced by the protein in peripheral blood mononuclear cells (PBMCs) and can also assess potential off-target binding to healthy cells and immune activation (immunotoxicity). The platform can also be used to assess the impact of a process change or product and process-related impurities on the immunogenicity risk.
Understanding the immune response against your leads in a fully human in vitro system during early development will allow you to manage potential safety risks prior to embarking on clinical trials.
The Epibase® in vitro assays use human peripheral blood mononuclear cells (PBMCs) and in some cases combined with other healthy human tissue cells provides researchers with a human in vitro system to more closely mimic the potential immune response of a patient in the clinic. Whole blood and leukopaks are collected at clinical sites adhering to ethically approved protocols.